Zacks Investment Research Equities Analysts Lift Earnings Estimates for CryoPort, Inc. (CYRX)
CryoPort, Inc. (NASDAQ:CYRX) – Research analysts at Zacks Investment Research lifted their Q3 2017 earnings per share (EPS) estimates for shares of CryoPort in a research report issued to clients and investors on Tuesday. Zacks Investment Research analyst B. Marckx now anticipates that the company will post earnings per share of ($0.08) for the quarter, up from their prior estimate of ($0.09). Zacks Investment Research also issued estimates for CryoPort’s Q4 2017 earnings at ($0.07) EPS, FY2017 earnings at ($0.32) EPS, FY2018 earnings at ($0.24) EPS and FY2019 earnings at ($0.12) EPS.
CryoPort (NASDAQ:CYRX) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01. CryoPort had a negative net margin of 102.89% and a negative return on equity of 67.75%. The company had revenue of $2.92 million during the quarter, compared to the consensus estimate of $2.84 million. ILLEGAL ACTIVITY WARNING: “Zacks Investment Research Equities Analysts Lift Earnings Estimates for CryoPort, Inc. (CYRX)” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/08/18/zacks-investment-research-equities-analysts-lift-earnings-estimates-for-cryoport-inc-cyrx.html.
Several other brokerages have also recently commented on CYRX. Cowen and Company increased their target price on CryoPort from $5.50 to $7.50 and gave the stock an “outperform” rating in a report on Wednesday, August 9th. Needham & Company LLC restated a “buy” rating and set a $6.00 target price on shares of CryoPort in a report on Thursday, July 13th. ValuEngine upgraded CryoPort from a “sell” rating to a “hold” rating in a report on Thursday, May 11th. Finally, Janney Montgomery Scott started coverage on CryoPort in a report on Wednesday, July 12th. They set a “buy” rating and a $8.00 target price on the stock.
CryoPort (NASDAQ:CYRX) opened at 7.96 on Friday. CryoPort has a one year low of $1.80 and a one year high of $8.23. The stock’s 50 day moving average is $6.17 and its 200 day moving average is $3.98. The firm’s market cap is $196.41 million.
Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of CryoPort by 96.9% in the second quarter. Vanguard Group Inc. now owns 519,100 shares of the company’s stock valued at $2,554,000 after buying an additional 255,519 shares during the last quarter. Taylor Wealth Management Partners acquired a new stake in shares of CryoPort during the second quarter valued at approximately $1,851,000. D.A. Davidson & CO. boosted its stake in shares of CryoPort by 16.6% in the second quarter. D.A. Davidson & CO. now owns 137,000 shares of the company’s stock valued at $674,000 after buying an additional 19,500 shares during the last quarter. EAM Investors LLC acquired a new stake in shares of CryoPort during the second quarter valued at approximately $552,000. Finally, BerganKDV Wealth Management LLC boosted its stake in shares of CryoPort by 157.5% in the second quarter. BerganKDV Wealth Management LLC now owns 25,750 shares of the company’s stock valued at $127,000 after buying an additional 15,750 shares during the last quarter. Institutional investors own 10.26% of the company’s stock.
Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.
Receive News & Ratings for CryoPort Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort Inc. and related companies with MarketBeat.com's FREE daily email newsletter.